TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: On the other hand, TP53 seems to be highly expressed in LSC, and, for this reason, developing strategies aimed at regulating orthogonal pathways, such as those associated with p53, could enhance the activity of TKI against CML stem cells [56,57].